Rezagiline use and synthesis methods

Parkinson's disease (PD) is a common chronic nervous system degenerative disease. All ages can be disease, but mostly in the elderly. With the aging of the population, its incidence increased year by year, and the incidence of young people showed a trend, to the family and society caused a heavy burden. L-dopa is still the most effective drug for the treatment of PD, but in the use of 2 to 5 years after the emergence of efficacy and long-term side effects, such as movement fluctuations (including the phenomenon of the end of the phenomenon, the phenomenon of switching and freezing phenomenon) And dyskinesia (including biphasic dyskinesia and dystonia).

Rasagiline (Rasagiline, trade name Azilect) is a Parkinson's disease treatment drug, by Lundbeck and Teva long-term alliance with the joint development of Parkinson's disease (PD) treatment drugs, is a new and effective second generation Selective monoamine oxidase B (MAO-B) inhibitors. The drug was first listed in Israel in January 2005 and subsequently approved by the European Union in February 2005 for the first time in June 2005 in the EU countries and has been approved by the FDA.

Raisagiline is an irreversible B-type monoamine oxidase (MAO-B) selective inhibitor that inhibits dopamine degradation and increases dopamine accumulation; while reducing synaptic membrane pre-dopamine uptake, promoting dopamine release, improving PD patients Clinical symptoms. It is in the prevention of tremor paralysis caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP) Bisi Li Gelan effective 5 times. The main metabolite of losagiline is 1- (R) -aminoindane without the addiction of amphetamines. In addition to inhibiting monoamine oxidase B, rasagiline can also prevent the opening of mitochondrial filtration pore, reduce the release of cytochrome C, alter the anti-apoptotic gene and protein, inhibit the transcription of glyceraldehyde-3-phosphate dehydrogenase, Nutritional factors. In clinical studies, rasagiline monotherapy is moderately effective and is effective in monotherapy or adjuvant treatment with levodopa, early and late PD drugs. Studies have confirmed that early use of rasagiline has a good effect on the treatment of tremor paralysis and may have delayed the role of the disease process and is now widely used clinically.

Welcome to Henan Tianfu Chemical Co., Ltd. website. Our company engages in Sodium Tripolyphosphate (STPP) and Sodium Hexametabphosphate (SHMP) production; development of noble metal catalysts, synthesis of electronic chemical materials and general chemicals Imp&Exp trading business. The company is located in Zhengzhou High-tech Development Zone with import and export license. We passed ISO 9001:2008 in 2009, and won "High-tech Enterprise" by provincial government in 2013. Our STPP and SHMP has reached an annual output of 30000 tons and has successfully passed SGS, CIQ audits on many occasions. 

 

In 2011 we entered the fine chemical market of Noble Metal Catalyst ,Organic Phosphine Ligands  and OLED intermediates.With the joint efforts of our senior experts and professional technicians, Tianfu has developed more than 500 compounds, which are widely used in the fields of production and life science. The objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal. Improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. We are constantly striving to make Henan Tianfu a leading chemical supplier, and hope to create a better future with you.